Yeung C K, Wong K L, Wong W S, Ng M T, Chan K W, Ng W L
Clin Nephrol. 1984 May;21(5):251-8.
Crescentic lupus glomerulonephritis (greater than or equal to 50% crescents) occurred in 16% of systemic lupus erythematosus (SLE) patients biopsied over a 32-month period. All had underlying WHO class IV lupus nephritis. These patients more frequently manifested with acute renal failure usually of the non-oliguric type, had heavier proteinuria and lower serum albumin, but were otherwise indistinguishable from non-crescentic WHO class IV lupus nephritis in their other renal and extrarenal manifestations or in their serological findings. Crescentic lupus glomerulonephritis may occur in patients at first presentation with SLE, or develop in patients after prolonged follow-up initially for lupus nephritis of WHO class IV or other classes. Combined methylprednisolone pulse therapy, immunosuppressives, antiplatelet agents with or without anticoagulant produced good initial responses. Prognosis was unfavorable for inadequately treated patients or for patients with persistent nephrotic syndrome and crescents.
在32个月的时间里,接受活检的系统性红斑狼疮(SLE)患者中有16%发生了新月体性狼疮性肾炎(新月体占比≥50%)。所有患者均有潜在的世界卫生组织(WHO)IV级狼疮性肾炎。这些患者更常表现为急性肾衰竭,通常为非少尿型,蛋白尿更严重,血清白蛋白更低,但在其他肾脏和肾外表现或血清学检查结果方面,与非新月体性WHO IV级狼疮性肾炎并无差异。新月体性狼疮性肾炎可能在SLE患者首次就诊时出现,或在最初因WHO IV级或其他级别的狼疮性肾炎进行长期随访的患者中发生。联合使用甲泼尼龙冲击疗法、免疫抑制剂、抗血小板药物(有或无抗凝剂)可产生良好的初始反应。对于治疗不充分的患者或患有持续性肾病综合征和新月体的患者,预后不佳。